Searched for: subject%3A%22Diphosphonates%22
(1 - 3 of 3)
van Beek, E.R. (author), Cohen, L.H. (author), Leroy, I.M. (author), Ebetino, F.H. (author), Löwik, C.W.G.M. (author), Papapoulos, S.E. (author), Gaubius Instituut TNO (author)
Bisphosphonates (BPS) inhibit bone resorption and are divided into two classes according to their chemical structure and mechanism of action: nonnitrogen containing BPS such as etidronate and clodronate that are of low potency and inhibit osteoclast function via metabolism into toxic ATP-metabolites and nitrogen-containing BPS (NBPS), such as...
article 2003
Teronen, O. (author), Laitinen, M. (author), Salo, T. (author), Hanemaaijer, R. (author), Heikkilä, P. (author), Konttinen, Y.T. (author), Sorsa, T. (author), TNO Preventie en Gezondheid (author)
article 2000
van Beek, E. (author), Pieterman, E. (author), Cohen, L. (author), Löwik, C. (author), Papapoulos, S. (author), Gaubius instituut TNO (author)
Bisphosphonates (Bps), inhibitors of osteoclastic bone resorption, are used in the treatment of skeletal disorders. Recent evidence indicated that farnesyl pyrophosphate (FPP) synthase and/or isopentenyl pyrophosphate (IPP) isomerase is the intracellular target(s) of bisphosphonate action. To examine which enzyme is specifically affected, we...
article 1999